Last reviewed · How we verify

artesunate-sulphadoxin/pyrimethamine, chloroquine — Competitive Intelligence Brief

artesunate-sulphadoxin/pyrimethamine, chloroquine (artesunate-sulphadoxin/pyrimethamine, chloroquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Infectious Diseases.

phase 3 Antimalarial Plasmodium falciparum Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

artesunate-sulphadoxin/pyrimethamine, chloroquine (artesunate-sulphadoxin/pyrimethamine, chloroquine) — University of Oxford. Artesunate-sulphadoxin/pyrimethamine works by inhibiting the growth of malaria parasites, while chloroquine targets the parasite's digestive enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
artesunate-sulphadoxin/pyrimethamine, chloroquine TARGET artesunate-sulphadoxin/pyrimethamine, chloroquine University of Oxford phase 3 Antimalarial Plasmodium falciparum
artesunate and mefloquine artesunate and mefloquine Mepha Ltd. marketed Antimalarial combination Plasmodium falciparum heme iron (artesunate); parasite digestive vacuole and mitochondria (mefloquine)
AS-AQ (Carsucam) AS-AQ (Carsucam) Centro de Investigacao em Saude de Manhica marketed Artemisinin-based combination therapy (ACT) Plasmodium falciparum (multiple parasite targets)
Artesunate + Amodiaquine Artesunate + Amodiaquine Professor Anders Björkman marketed Antimalarial combination Plasmodium falciparum hemoglobin metabolism and DNA synthesis
SP-IPTp SP-IPTp London School of Hygiene and Tropical Medicine marketed Antimalarial combination therapy Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine)
Chloroquine prophylaxis Chloroquine prophylaxis Radboud University Medical Center marketed Antimalarial; immunomodulator Plasmodium falciparum heme detoxification pathway; toll-like receptors
artemisinin/naphthoquine artemisinin/naphthoquine Ifakara Health Institute marketed Antimalarial combination Plasmodium falciparum heme metabolism and mitochondrial electron transport

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

  1. London School of Hygiene and Tropical Medicine · 6 drugs in this class
  2. Sanofi · 3 drugs in this class
  3. Epicentre · 2 drugs in this class
  4. University of Oxford · 2 drugs in this class
  5. · 2 drugs in this class
  6. Frantz Viral Therapeutics, LLC · 1 drug in this class
  7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  8. Institut de Recherche pour le Developpement · 1 drug in this class
  9. Centre de Recherche Médicale de Lambaréné · 1 drug in this class
  10. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). artesunate-sulphadoxin/pyrimethamine, chloroquine — Competitive Intelligence Brief. https://druglandscape.com/ci/artesunate-sulphadoxin-pyrimethamine-chloroquine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: